0.3239
前日終値:
$0.305
開ける:
$0.286
24時間の取引高:
3.91M
Relative Volume:
2.20
時価総額:
$83.32M
収益:
$175.04M
当期純損益:
$-44.52M
株価収益率:
-1.7994
EPS:
-0.18
ネットキャッシュフロー:
$-56.05M
1週間 パフォーマンス:
+47.23%
1か月 パフォーマンス:
-36.58%
6か月 パフォーマンス:
-63.81%
1年 パフォーマンス:
-76.53%
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Company Profile
名前
Adaptimmune Therapeutics Plc Adr
セクター
電話
44 1235 430000
住所
60 JUBILEE AVENUE, ABINGDON, OXFORDSHIRE
ADAP を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
ADAP
Adaptimmune Therapeutics Plc Adr
|
0.3239 | 83.32M | 175.04M | -44.52M | -56.05M | -0.18 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 66.76B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-07-30 | 開始されました | H.C. Wainwright | Buy |
2024-05-30 | 開始されました | Scotiabank | Sector Outperform |
2023-03-24 | 開始されました | Bryan Garnier | Buy |
2023-01-03 | アップグレード | Guggenheim | Neutral → Buy |
2022-11-09 | アップグレード | Mizuho | Neutral → Buy |
2021-05-28 | 開始されました | Barclays | Underweight |
2020-04-22 | 開始されました | Mizuho | Neutral |
2019-08-02 | ダウングレード | Guggenheim | Buy → Neutral |
2019-05-31 | 開始されました | ROTH Capital | Buy |
2019-05-30 | 再開されました | Citigroup | Buy |
2019-05-07 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
2017-03-17 | 開始されました | Wells Fargo | Market Perform |
2016-10-24 | ダウングレード | BofA/Merrill | Neutral → Underperform |
2016-09-30 | 開始されました | Raymond James | Outperform |
2016-02-25 | 開始されました | Citigroup | Buy |
2015-06-01 | 開始されました | BofA/Merrill | Neutral |
2015-06-01 | 開始されました | Guggenheim | Buy |
2015-06-01 | 開始されました | Leerink Partners | Outperform |
すべてを表示
Adaptimmune Therapeutics Plc Adr (ADAP) 最新ニュース
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Today’s Hot Stock - stocksregister.com
H.C. Wainwright cuts Adaptimmune stock target to $3, maintains Buy By Investing.com - Investing.com South Africa
H.C. Wainwright cuts Adaptimmune stock target to $3, maintains Buy - Investing.com India
Guggenheim cuts Adaptimmune target to $1.75, maintains Buy By Investing.com - Investing.com South Africa
Guggenheim cuts Adaptimmune target to $1.75, maintains Buy - Investing.com India
Adaptimmune Therapeutics Amends Loan Agreement - Investing.com India
Scotiabank cuts Adaptimmune price target to $1.40, keeps rating By Investing.com - Investing.com South Africa
Scotiabank cuts Adaptimmune price target to $1.40, keeps rating - Investing.com
Mizuho maintains Outperform on Adaptimmune, price target $1.50 By Investing.com - Investing.com South Africa
Mizuho maintains Outperform on Adaptimmune, price target $1.50 - Investing.com
Earnings call transcript: Adaptimmune Q4 2024 targets $25M sales in 2025 - Investing.com
Adaptimmune Therapeutics PLC Sponsored ADR to Host Earnings Call - ACCESS Newswire
LAG-3 Immunotherapies Market Set for Rapid Growth in the Coming 10 Years Across the 7MM as Next-Generation Therapies Advance | DelveInsight - GlobeNewswire Inc.
Analysts Recommend Holding Your Position In Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) - Stocks Register
Investing in Adaptimmune Therapeutics Plc ADR (ADAP) Is Getting More Attractive - Knox Daily
Potential Price Increase for Coterra Energy Inc (CTRA) After Recent Insider Activity - Knox Daily
Taking a Closer Look At Dollar Tree Inc (DLTR) Following Its Recent Trade - Knox Daily
A Guide To The Risks Of Investing In Agilon Health Inc (AGL) - Knox Daily
Daily Progress: Quanterix Corp (QTRX) Drop -3.57, Closing at 7.83 - The Dwinnex
Following A 4.11% Weekly Incline, Is It Still A Buy For Amylyx Pharmaceuticals Inc (NASDAQ: AMLX)? - Marketing Sentinel
Should Outset Medical Inc (NASDAQ: OM) Rally After -544.44% Drop From High? - Marketing Sentinel
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Stock Falling -5.24% Over A Month – Any Room For Its Value To Rise? – Marketing Sentinel - Marketing Sentinel
BioVie Inc (NASDAQ: BIVI): How Can A Stock Be Down -4.00% Year To Date, But Still Loser - Marketing Sentinel
Adaptimmune Therapeutics Plc ADR (ADAP) Stock: A Closer Look at the Moving Averages - The News Heater
SM Energy Co (SM): A Technical Analysis - The News Heater
Adaptimmune Therapeutics Plc ADR (ADAP)’s stock price in review: A technical analysis - US Post News
Quarterly Snapshot: Quick and Current Ratios for Adaptimmune Therapeutics Plc ADR (ADAP) - The Dwinnex
Adaptimmune therapeutics COO sells shares worth $3,243 - Investing.com India
Adaptimmune therapeutics' chief medical officer sells $3,243 in stock By Investing.com - Investing.com South Africa
Adaptimmune therapeutics' chief medical officer sells $3,243 in stock - Investing.com India
Adaptimmune therapeutics COO sells shares worth $3,243 By Investing.com - Investing.com South Africa
Adaptimmune therapeutics COO William Bertrand sells $11,360 in shares - Investing.com India
Adaptimmune therapeutics' chief medical officer sells $12,920 in shares - Investing.com
Adaptimmune's chief commercial officer sells $7,467 in shares - Investing.com
AST SpaceMobile Inc Still Hasn’t Convinced Analysts? - Stocks Register
These Numbers Show Just How Powerful Standard Lithium Ltd (AMEX: SLI) Stock Is - Stocks Register
What Did We Note About Insider Trading At Lithium Americas Corp (NewCo) (NYSE: LAC)? - Stocks Register
Workhorse Group Inc (NASDAQ: WKHS) Could Pass $3.5 In One Year Stock Forecast - Stocks Register
Barnes & Noble Education Inc (NYSE: BNED) -10.53% Decline Turns Investors Away - Stocks Register
Applied Digital Corporation (NASDAQ: APLD) Could Pass $10 In One Year Stock Forecast - Stocks Register
Asana Inc (NYSE: ASAN) Up 15.57% This Year: What Is Going To Happen Next - Stocks Register
Adaptimmune's SWOT analysis: TCR-T pioneer faces challenges in stock outlook - Investing.com
Adaptimmune's SWOT analysis: TCR-T therapy pioneer faces challenges post-FDA nod - Investing.com
Royal Dutch Shell Plc ADR (SHEL-N) QuotePress Release - The Globe and Mail
Mizuho lowers Adaptimmune price target by 50%, citing pipeline shifts and cost cuts - Investing.com
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT)’s Stock Reduces -12.58%, Making It A Good Investment - Stocks Register
Analysts Predict Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) To Loss -577.97% From Current Levels. - Stocks Register
Earnings call: Adaptimmune outlines new strategy amid Tecelra launch By Investing.com - Investing.com South Africa
Adaptimmune stock holds Buy rating with lower target amid Q3 revenue outperformance - Investing.com
ADAPAdaptimmune Therapeutics plc American Depositary Shares Latest Stock News & Market Updates - StockTitan
Adaptimmune faces Nasdaq delisting over share price - Investing.com India
Adaptimmune Therapeutics Plc Adr (ADAP) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):